Back to results
US 2024/0197709 A1Published application
Potentiating the tumor-selective effects of nqo1-bioactivatable agent by use of cmet inhibitor
OwnerEdward Ayson Motea, Snehal Bhandareinventors
Life of this patent
Estimating the term…
Abstract
Methods are provided for treating cancer, particularly non-small cell lung cancers and pancreatic ductal adenocarcinomas, by administering both a sublethal dose of NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable drug and a sublethal dose of mesenchymal-epithelial transition factor (cMET) inhibitor to the cancer patient. Treatment of other cancers which overexpress cMET and NQO1 are also provided.
Claims20
A method of treating cancer in a subject in need thereof comprising:
- administering to the subject a NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable drug;
- and
- administering to the subject a mesenchymal-epithelial transition factor (cMET) inhibitor.
The method of claim 9 wherein the NQO1 bioactivatable drug is β-lapachone (β-lap).
Dependencies are inferred from the claim text.